Korlym’s Mechanism Of Action Complicated Cushing’s Trial Design
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The standard measure of efficacy in Cushing’s syndrome – reduced cortisol levels – is not applicable to mifepristone, which blocks the biological effect of cortisol at the receptor level. Corcept needed to select clinical endpoints from among the multisystem manifestations of Cushing’s syndrome.